{"id":914,"date":"2020-08-26T14:36:19","date_gmt":"2020-08-26T14:36:19","guid":{"rendered":"https:\/\/interhospi.3wstaging.nl\/simple-step-reduces-bladder-cancer-recurrence\/"},"modified":"2020-08-26T14:36:26","modified_gmt":"2020-08-26T14:36:26","slug":"simple-step-reduces-bladder-cancer-recurrence","status":"publish","type":"post","link":"https:\/\/interhospi.com\/simple-step-reduces-bladder-cancer-recurrence\/","title":{"rendered":"Simple step reduces bladder cancer recurrence"},"content":{"rendered":"

Flushing the bladder with a common chemotherapy drug immediately after surgery significantly reduces the chances of bladder cancer returning, according to a major study by SWOG, an international clinical trials network funded by the National Cancer Institute.<\/span>
\nThe research was led by Edward M. Messing, MD, a SWOG investigator and professor of urology, and a professor of oncology and pathology, at the University of Rochester School of Medicine and Dentistry and a physician at the Wilmot Cancer Institute. <\/span>
\nThe study notes this may be the first phase III trial in the U.S. to show a benefit from this treatment strategy in two decades. European and Canadian urologists have been using it for years, with their own clinical trial data to support the procedure.<\/span>
\n\u201cThe real importance of this study is that we now have a readily available drug that\u2019s fairly inexpensive, well-tolerated, and effective,\u201d Messing said. \u201cOne of the biggest issues with low-grade bladder cancer is that it frequently returns. I know some patients who have to undergo four surgeries a year, and if we can cut down on these recurrences, we will save a lot of people a lot of pain, money, and time lost to recovery.\u201d<\/span>
\nThe study says the findings \u201csupport using this therapy,\u201d but adds that further research is needed to compare various chemotherapy agents for their effectiveness. About 80,000 Americans a year are diagnosed with bladder cancer, and the low-grade non-muscle invasive form makes up about half of the new cases annually. A JAMA editorial on the work states: "The thoughtfully designed, executed, and interpreted study by Messing et al provides important results for patients and physicians alike, to the extent that the investigators focused on a problem with meaningful implications for individual patients, population health, and the value of care." <\/span>
\nThe SWOG team conducted the randomized, double-blind clinical trial involving 406 eligible patients at 23 cancer centers. <\/span>
\nSurgeons removed all cancerous tissue with a procedure known as TURBT, or transurethral resection of bladder tumour. Then, 201 patients received the chemotherapy drug, gemcitabine, mixed with saline, administered via catheter to the bladder area within three hours after surgery. Gemcitabine works by blocking new DNA and killing any dividing cells. It\u2019s used to treat several other cancers, including advanced bladder cancer, but had not been studied in this setting among low-grade cancer patients. The second group of 205 patients received saline alone.<\/span>
\nResearchers followed all patients for four years \u2014 the time period when most bladder cancers return \u2014 seeking to discover which treatment strategy worked better. The results were clear: A 34 percent reduction in the risk of recurrence for patients receiving the gemcitabine infusion. Sixty-seven patients in the gemcitabine group, or 35 percent, experienced a recurrence, compared with 91 patients in the saline group, or 47 percent.<\/span><\/p>\n

SWOGwww.swog.org\/news-events\/news\/2018\/05\/08\/simple-step-reduces-bladder-cancer-recurrence<\/link><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Flushing the bladder with a common chemotherapy drug immediately after surgery significantly reduces the chances of bladder cancer returning, according to a major study by SWOG, an international clinical trials network funded by the National Cancer Institute. The research was led by Edward M. Messing, MD, a SWOG investigator and professor of urology, and a […]<\/p>\n","protected":false},"author":2,"featured_media":638,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-914","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-e-news"],"_links":{"self":[{"href":"https:\/\/interhospi.com\/wp-json\/wp\/v2\/posts\/914"}],"collection":[{"href":"https:\/\/interhospi.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/interhospi.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/interhospi.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/interhospi.com\/wp-json\/wp\/v2\/comments?post=914"}],"version-history":[{"count":1,"href":"https:\/\/interhospi.com\/wp-json\/wp\/v2\/posts\/914\/revisions"}],"predecessor-version":[{"id":10882,"href":"https:\/\/interhospi.com\/wp-json\/wp\/v2\/posts\/914\/revisions\/10882"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/interhospi.com\/wp-json\/wp\/v2\/media\/638"}],"wp:attachment":[{"href":"https:\/\/interhospi.com\/wp-json\/wp\/v2\/media?parent=914"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/interhospi.com\/wp-json\/wp\/v2\/categories?post=914"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/interhospi.com\/wp-json\/wp\/v2\/tags?post=914"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}